Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

W1131 is a STAT3 inhibitor.1 It selectively inhibits the phosphorylation of STAT3 over STAT1, STAT5, JAK2, and Akt in AGS gastric adenocarcinoma cells at 3 µM. W1131 binds to STAT3 in a cell-free assay (Kd = 7.55 µM) and increases the thermal stability of STAT3 in a cellular thermal shift assay (CETSA) using AGS cells when used at a concentration of 1 µM. It also inhibits STAT3 dimerization, nuclear accumulation, and transcriptional activation in cell-based assays. W1131 (3 µM) induces cell death in AGS cells, which can be reversed by Z-VAD-FMK (Z-VA-DL-D(OMe)-FMK; Item No. 27421), ferrostatin-1 (Item No. 17729), liproxstatin-1 (Item No. 17730), deferoxamine (DFO; Item No. 14595), necrosulfonamide (Item No. 20844), or bafilomycin A1 (Item No. 11038). In vivo, W1131 (10 mg/kg) decreases tumor volume and weight in 5-fluorouracil-sensitive and -resistant MGC803 gastric cancer mouse xenograft models.
WARNING This product is not for human or veterinary use.
1. Inhibition of STAT3-